Meeting
2023 ASCO Annual Meeting
Effect of personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma on TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.
Authors
Renzo Perales
Geneos Therapeutics, Plymouth Meeting, PA
Renzo Perales , Neil Cooch , Mark Yarchoan , Niranjan Y. Sardesai , Jian Yan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2629)
DOI
10.1200/JCO.2023.41.16_suppl.2629
Abstract #
2629
Poster Bd #
471
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.
First Author: Mark Yarchoan
Poster
2022 ASCO Annual Meeting
Personalized neoantigen DNA vaccines expand tumor-specific T cells in the periphery which infiltrate the tumor in hepatocellular carcinoma.
First Author: Renzo Perales
Poster
2023 ASCO Annual Meeting
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
First Author: Sofie Kirial Mørk
Poster
2021 ASCO Annual Meeting
A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer.
First Author: Aaron Miller